- Conditions
- Prostate Cancer
- Interventions
- Plenaxis
- Drug
- Lead sponsor
- PRAECIS Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 54 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 409–432
of 953
matching trials from the live ClinicalTrials.gov search.
- Conditions
- FSGS
- Interventions
- DMX-200, Placebo
- Drug
- Lead sponsor
- Dimerix Bioscience Pty Ltd
- Industry
- Eligibility
- 12 Years to 80 Years
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 44 more
- Conditions
- Embolization, Vascular Tumor, Renal Angiomyolipoma, Renal Cell Carcinoma, Bone Tumor, Portal Vein Embolization
- Interventions
- GPX® Embolic Device
- Device
- Lead sponsor
- Fluidx Medical Technology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 15
- States / cities
- La Jolla, California • Aurora, Colorado • Chicago, Illinois + 11 more
- Conditions
- Graft-versus-Host Disease, Immune System Disorders
- Interventions
- Mycophenolate Mofetil, Placebo
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- Not listed
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 36
- States / cities
- Duarte, California • La Jolla, California • Stanford, California + 28 more
- Conditions
- Breast Cancer
- Interventions
- systemic chemotherapy, axillary lymph node dissection, neoadjuvant therapy, sentinel lymph node biopsy, therapeutic conventional surgery, ultrasound imaging
- Drug · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 756 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2023
- U.S. locations
- 324
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 232 more
- Conditions
- Cognition, Aging
- Interventions
- tamoxifen, raloxifene
- Drug
- Lead sponsor
- Wake Forest University
- Other
- Eligibility
- 65 Years and older · Female only
- Enrollment
- 1,498 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2001 – 2008
- U.S. locations
- 127
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Camp Pendleton, California + 102 more
- Conditions
- Eyelid Squamous Cell Carcinoma, Recurrent Eyelid Squamous Cell Carcinoma, Recurrent Skin Acantholytic Squamous Cell Carcinoma, Recurrent Skin Clear Cell Squamous Cell Carcinoma, Recurrent Skin Lymphoepithelial Carcinoma, Recurrent Skin Spindle Cell Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Resectable Eyelid Squamous Cell Carcinoma, Resectable Skin Acantholytic Squamous Cell Carcinoma, Resectable Skin Clear Cell Squamous Cell Carcinoma, Resectable Skin Lymphoepithelial Carcinoma, Resectable Skin Spindle Cell Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Skin Acantholytic Squamous Cell Carcinoma, Skin Clear Cell Squamous Cell Carcinoma, Skin Lymphoepithelial Carcinoma, Skin Spindle Cell Squamous Cell Carcinoma, Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
- Interventions
- Biospecimen Collection, Cemiplimab, Computed Tomography, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Surgical Procedure
- Procedure · Biological · Radiation + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 196
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 147 more
- Conditions
- Paroxysmal Supraventricular Tachycardia
- Interventions
- Etripamil, Placebo, Etripamil Test Dose
- Drug
- Lead sponsor
- Milestone Pharmaceuticals Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,097 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 54
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Cerritos, California + 44 more
- Conditions
- Lung Cancer
- Interventions
- Standard Radiation Dose Therapy, cisplatin, etoposide, High Radiation Dose Therapy, carboplatin
- Radiation · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 731 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2026
- U.S. locations
- 930
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 575 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Filgotinib, Placebo to match filgotinib
- Drug
- Lead sponsor
- Alfasigma S.p.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,731 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 72
- States / cities
- Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 65 more
- Conditions
- Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Interventions
- Apalutamide, Bicalutamide, Biospecimen Collection, Bone Scan, Buserelin, Computed Tomography, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Magnetic Resonance Elastography, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Relugolix, Triptorelin
- Drug · Procedure · Other + 1 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 2,753 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2038
- U.S. locations
- 594
- States / cities
- Fairbanks, Alaska • Gilbert, Arizona • Peoria, Arizona + 438 more
- Conditions
- Heart Failure
- Interventions
- Usual Care, Biomarker-guided care NT-proBNP
- Other · Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 894 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 40
- States / cities
- Huntsville, Alabama • Sacramento, California • San Diego, California + 33 more
- Conditions
- HIV Infection
- Interventions
- Elvitegravir, Raltegravir, EVG placebo, RAL placebo, Background regimen
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 724 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 94
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 59 more
- Conditions
- Articular Fractures
- Interventions
- Single Implant Fixation, Dual Implant Fixation
- Procedure
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia + 13 more
- Conditions
- Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma, Metastatic Embryonal Rhabdomyosarcoma, Metastatic Rhabdomyosarcoma, Solid Alveolar Rhabdomyosarcoma, Spindle Cell Rhabdomyosarcoma, Spindle Cell/Sclerosing Rhabdomyosarcoma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Cyclophosphamide, Dactinomycin, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy, Vincristine Sulfate, Vinorelbine Tartrate, X-Ray Imaging
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 50 Years
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 228
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 160 more
- Conditions
- Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
- Interventions
- Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate, Echocardiography Test, Multigated Acquisition Scan, Positron Emission Tomography, Trametinib Dimethyl Sulfoxide
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 752
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 464 more
- Conditions
- Lung Cancer
- Interventions
- erlotinib hydrochloride, gemcitabine hydrochloride
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 70 Years to 120 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 11
- States / cities
- Fayetteville, Arkansas • Savannah, Georgia • Evanston, Illinois + 8 more
- Conditions
- Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Neuroblastoma
- Interventions
- Biopsy Procedure, Bone Marrow Aspiration, Bone Marrow Biopsy, Carboplatin, Clinical Observation, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Magnetic Resonance Imaging, Ultrasound
- Procedure · Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 18 Months
- Enrollment
- 391 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 193
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 147 more
- Conditions
- Kidney Cancer
- Interventions
- dactinomycin, filgrastim, cyclophosphamide, doxorubicin hydrochloride, etoposide, vincristine sulfate, conventional surgery, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 0 Years to 15 Years
- Enrollment
- 3,031 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2003
- U.S. locations
- 206
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
- Conditions
- Sickle Cell Disease
- Interventions
- NDec - oral decitabine-tetrahydrouridine, HU - Hydroxyurea, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 53
- States / cities
- Mobile, Alabama • Los Angeles, California • Oakland, California + 37 more
- Conditions
- Adenocarcinoma of the Rectum, Stage II Rectal Cancer, Stage III Rectal Cancer
- Interventions
- oxaliplatin, fluorouracil, leucovorin calcium, bevacizumab
- Drug
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 355 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2019
- U.S. locations
- 600
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 386 more
- Conditions
- Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
- Interventions
- Kidney Biopsy
- Procedure
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- Up to 80 Years
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2030
- U.S. locations
- 39
- States / cities
- Los Angeles, California • Palo Alto, California • San Francisco, California + 26 more
- Conditions
- Crohn's Disease
- Interventions
- Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Guselkumab Dose 4, Guselkumab Dose 5, Guselkumab, Ustekinumab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,409 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 109
- States / cities
- Dothan, Alabama • Mobile, Alabama • Tucson, Arizona + 83 more
- Conditions
- Myeloproliferative Neoplasms
- Interventions
- INCA036978, Standard disease-directed therapy
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Irvine, California • Los Angeles, California + 17 more